ConductScience.org, home

Comparison · NCT04685538-sae

Chloroprocaine 3% vs Tetracaine 0.5%: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Chloroprocaine 3% vs Tetracaine 0.5%: serious adverse events. Trial comparisons, record NCT04685538-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04685538-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 1000.0225wilson
Risk in group 2000.022wilson
Risk difference, group 1 minus group 20-0.0220.0225newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to harmfrom the risk difference intervalthe two groups' risks are equal

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Chloroprocaine 3%
All the eligible patients will be administrated by Chloroprocaine 3 % according to the randomization criteria.~Chloroprocaine 3%: Administration: three IMP drops instillation as follow:~* 1st Drop instillation, then wait for 5 minutes~* Eye Disinfection, then wait for 2 minutes~* 2nd Drop instillation, then wait for 1 minute~* 3rdDrop instillation, then wait for 1 minute~* Start of Surgery.
0167EG000
Group 2Tetracaine 0.5%
All the eligible patients will be administrated by Tetracaine 0.5% according to the randomization criteria.~Tetracaine 0.5%: Administration: three IMP drops instillation as follow:~* 1st Drop instillation, then wait for 5 minutes~* Eye Disinfection, then wait for 2 minutes~* 2nd Drop instillation, then wait for 1 minute~* 3rdDrop instillation, then wait for 1 minute~* Start of Surgery.
0171EG001

Harm

What it counts
Total, serious adverse events
Time frame
Adverse events were to be monitored throughout the course of the study Visit 1 (Day -90/Day -1) and Visit 4 (Day 8 ± 1 day)) up to Visit 5 (Day 28 ± 3 days; approximately 129 days

Source ClinicalTrials.gov

Trial

Title
Chloroprocaine 3% Gel Eye Drop as Topical Anestheticsin Phacoemulsification.
NCT number
NCT04685538
Phases
PHASE3
Conditions
Cataract
Interventions
Chloroprocaine 3%, Tetracaine 0.5%
Lead sponsor
Sintetica SA
Results first posted
2022-10-27

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04685538-sae